The Promise for ARU-1801, a Differentiated Lentiviral Vector Gene Therapy for Sickle Cell Disease

Time: 3:00 pm
day: Day Two


  • Introduction to Aruvant’s gene therapies for rare diseases
  • Overview of how ARU-1801 is a differentiated investigational gene therapy for individuals living with severe sickle cell disease
  • A review of recent data from Aruvant’s ongoing MOMENTUM study in individuals with sickle cell disease